FranklinMaxwellHalleyMD

PubMed

• Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics.
  Lesuisse, D., Tiraboschi, G., Krick, A., Abecassis, P. Y., Dutruc-Rosset, G., Babin, D., Halley, F., Châtreau, F., Lachaud, S., Chevalier, A., Quarteronet, D., Burgevi...> ;Bioorg Med Chem Lett. 2010 Apr 1
• Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2.
  Lesuisse, D., Dutruc-Rosset, G., Tiraboschi, G., Dreyer, M. K., Maignan, S., Chevalier, A., Halley, F., Bertrand, P., Burgevin, M. C., Quarteronet, D., Rooney, T.> ;Bioorg Med Chem Lett. 2010 Mar 15
• An algorithm-directed two-component library synthesized via solid-phase methodology yielding potent and orally bioavailable p38 MAP kinase inhibitors.
  McKenna, J. M., Halley, F., Souness, J. E., McLay, I. M., Pickett, S. D., Collis, A. J., Page, K., Ahmed, I.> ;J Med Chem. 2002 May 23